Core Viewpoint - The innovative drug sector is experiencing a strong rally, with significant growth potential driven by global business development (BD) authorizations and advanced technology platforms [3][4]. Group 1: Industry Trends - The innovative drug market is expected to see continuous BD authorizations, which are crucial for driving the next wave of growth and revenue [3]. - Advanced technology platforms such as ADC, bispecific antibodies, and CAR-T are leading the innovation in the post-PD-1 era, positioning Chinese innovative drug companies at the forefront globally [3]. - China is leading in the ADC field, with a significant number of reports presented at ASCO, indicating a strong presence in the global market [3]. - The bispecific antibody pipeline in China accounts for nearly 50% of the global pipeline, with impressive clinical data and a projected 14 products expected to enter international markets in 2024, surpassing $10 billion in total transaction value [3]. Group 2: Upcoming Events and Opportunities - Key industry conferences such as WCLC and ESMO are anticipated to showcase the latest clinical research from Chinese innovative drug companies, serving as potential catalysts for the sector [4]. - High-demand disease areas, including weight loss and autoimmune diseases, present significant unmet clinical needs, offering expansive future market opportunities [4]. - Policy support, including optimization of medical insurance access and the introduction of new categories, is crucial for the continued growth of the innovative drug sector [4]. Group 3: Investment Strategies - The innovative drug sector is viewed as a long-term investment opportunity, with public funds gradually recovering after previous declines [5]. - Investors are encouraged to adopt a strategy of buying on dips, particularly focusing on the innovative drug ETF from Guotai (517110), which provides a balanced exposure to major innovative drug companies across A-shares and Hong Kong stocks [5]. - Notable companies in the innovative drug space include Heng Rui Medicine, King’s Ray Biotechnology, BeiGene, and others, which are recommended for consideration [5].

Core Insights - The report indicates that the current market sentiment is at a high level, with a score of 88, categorizing it as "overheated" [6][10][22] - Recent policy support and improved market sentiment have contributed to a bullish trend in the market [10] Market Themes Tracking - **Data Theme**: The National Data Bureau and the State Administration for Market Regulation have introduced measures to enhance data circulation efficiency, potentially increasing efficiency by 30% [7] - **Cross-Border Payment Theme**: The People's Bank of China has released a draft for the rules governing the Renminbi cross-border payment system, aiming to simplify participation conditions for foreign institutions [7] - **Innovative Drug Theme**: The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research [7] Major Capital Inflows - The report lists the top ten stocks with significant net inflows, including Zhongyou Capital (90.12 million), Pengding Holdings (64.11 million), and others [11][12] Major Capital Outflows - The report also highlights the top ten stocks with significant net outflows, such as Changshan Pharmaceutical (-83.03 million) and Jinyi Culture (-79.62 million) [13][23] Financing and Margin Trading - The report provides insights into financing net purchases and margin trading, indicating investor sentiment towards specific stocks and sectors [23]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.30%, outperforming the CSI 300 index which rose by 3.52% during the reporting period [3][14] - The PE ratio (TTM, excluding negative values) for the pharmaceutical and biotechnology industry as of July 4, 2025, is 28.52x, up from 27.28x in the previous period, indicating an upward trend in valuation [3][19] - Notable sub-industries include "Other Biological Products" and "Medical R&D Outsourcing," which saw increases of 11.20% and 9.37% respectively, while "Medical Equipment" and "Blood Products" lagged with increases of only 0.98% [3][14] Industry Trends - The report highlights significant policy measures from the National Healthcare Security Administration and the National Health Commission aimed at supporting the high-quality development of innovative drugs [5][6] - The introduction of a commercial health insurance innovative drug directory is a key breakthrough, facilitating better pricing and reimbursement mechanisms for high-value drugs [6] - The report emphasizes the importance of the innovative drug industry chain, particularly focusing on platform pharmaceutical companies, clinical CROs, and high-barrier CDMOs [6] Important Industry News - The approval of several innovative drugs, including "ZEGFROVY" by Dize Pharmaceutical and "TQG203" by Zhengda Tianqing, marks significant advancements in the industry [41][42][46] - The report notes that the global number of hemophilia patients is expected to increase by 25% by 2025, highlighting the growing market for innovative treatments [42] - The approval of "Mastrudep" by Innovent Biologics for weight management in adults showcases the expanding therapeutic applications of GLP-1R/GCGR dual agonists [49][50] Investment Recommendations - Continuous attention is recommended for the innovative drug industry chain, particularly for companies that can navigate the new dual directory system and have international expansion capabilities [6] - The report suggests that the recent policy changes and the successful IPO of a biotech company signal a positive outlook for the innovative drug sector [6]

Core Insights - The report indicates a neutral market sentiment with a score of 56, suggesting a balanced outlook for investors [2][10] - Key themes identified include photovoltaic, energy metals, and innovative pharmaceuticals, with specific companies highlighted for potential investment opportunities [7] Market Sentiment - The market sentiment temperature indicator shows a score of 56, categorized as "neutral," indicating moderate market fluctuations and stable investor emotions [6][10] - Historical trends suggest that when the sentiment score is below 30, the market tends to find support, while scores above 90 may indicate resistance [10] Hot Themes Tracking - **Photovoltaic Theme**: Major domestic photovoltaic glass companies plan to collectively reduce production by 30% starting July, which is expected to improve the supply-demand imbalance in the market. Projected domestic glass production is expected to drop to around 45GW in July. Related companies include Quartz Co., Ltd. (603688) and Aiko Solar (600732) [7] - **Energy Metals Theme**: The Democratic Republic of Congo has extended a temporary ban on cobalt exports due to high inventory levels, effective from June 21, 2025. Related companies include Huayou Cobalt (603799) and Tianqi Lithium (002466) [7] - **Innovative Pharmaceuticals Theme**: The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development. Related companies include Heng Rui Medicine (600276) and Betta Pharmaceuticals (300558) [7] Major Capital Flows - The report lists the top ten stocks with significant net inflows, including Wolong Nuclear Materials (002130) with a net inflow of 119,369.13 million and Xiexin Energy Technology (002015) with 52,418.61 million [11] - The top ten stocks with significant net outflows include Zhongji Xuchuang (300308) with a net outflow of -56,351.46 million and Haoshanghao (001298) with -49,377.86 million [13] Industry Overview - The report highlights the performance of various industries, with significant net inflows observed in sectors such as computer and media, while notable outflows were seen in pharmaceuticals and banking [17][18]

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, particularly focusing on PD-1/VEGF dual antibodies [1]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 3.64%, outperforming the Shanghai Composite Index (1.54%) and the Wind All A Index (1.22%). The PD-1/VEGF related stocks led the gains, with other biopharmaceuticals rising by 8.28% [2][7]. - A significant partnership was announced between Bristol-Myers Squibb (BMS) and BioNTech, involving a $11.1 billion agreement to co-develop and commercialize BioNTech's PD-L1/VEGF dual-specific antibody BNT327. This highlights the strategic importance of PD-1/VEGF dual antibodies in the global market [2][3]. - The report emphasizes the increasing interest from multinational corporations (MNCs) in the PD-1/VEGF dual antibody space, suggesting that domestic biotech firms are well-positioned for future business development (BD) opportunities [2][3]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector experienced a 3.64% increase, with notable performances from individual stocks such as Seer Medical (51.5%), Guangsheng Tang (48.6%), and Shenzhou Cell-U (45%) [7][10]. - The report notes that the other biopharmaceuticals sector rose by 8.28%, while medical devices and hospitals saw slight declines [2][7]. Industry News and Key Company Announcements - On July 1, the National Healthcare Security Administration released proposals for the adjustment of the 2025 National Basic Medical Insurance drug catalog, aiming to support innovative drug development [12]. - Significant approvals were noted, including the launch of TQG203 for treating hemophilia and the approval of Liraglutide for obstructive sleep apnea [12][13]. - Strategic investments were highlighted, such as Sanofi's investment in Tianyan Pharmaceutical, which will support the development of SAFEbody antibodies [15]. Company Announcements - Several companies reported significant developments, including the approval of new drugs and strategic partnerships aimed at enhancing their market positions [15][16]. - Notably, the report mentions the approval of innovative drugs that address unmet medical needs, indicating a trend towards more targeted therapies in the market [12][13].

Core Viewpoint - The delayed payment of 180 million yuan by Betta Pharmaceuticals to Yifang Biologics for milestone payments related to the drug Beifuzi has raised concerns about the financial health and operational integrity of both companies [1][2][5]. Company Overview - Yifang Biologics developed Beifuzi, a first-in-class innovative drug for lung cancer, and granted commercial rights to Betta Pharmaceuticals in December 2018 [2][3]. - Betta Pharmaceuticals was supposed to pay a total of 230 million yuan in milestone payments based on the drug's development progress, which includes regulatory approvals for various treatment indications [2][4]. Financial Performance - Yifang Biologics reported zero revenue from 2020 to 2022, but began generating income in 2023, totaling 186 million yuan, primarily from technical authorization and cooperation [4][8]. - As of the end of 2023, Yifang Biologics had accounts receivable of 186 million yuan, with a provision for bad debts of 9.29 million yuan, indicating reliance on Betta Pharmaceuticals for revenue [4][5]. Payment Delays - Betta Pharmaceuticals has delayed payments for two years, with the outstanding amount of 180 million yuan due to its own financial management considerations [5][10]. - The company has acknowledged the overdue payments and stated that it will fulfill its obligations according to the agreement [5][7]. Market Competition - Beifuzi's market entry is hindered by its later approval compared to competitors like Osimertinib and Alectinib, which have annual sales in the range of 3 to 4 billion yuan [8][9]. - Yifang Biologics has reported sales-related income from Beifuzi of approximately 5.53 million yuan in 2023 and 16.38 million yuan in 2024, indicating a significant gap in sales compared to established competitors [8][9]. Financial Health of Betta Pharmaceuticals - As of the end of 2024, Betta Pharmaceuticals had cash reserves of 472 million yuan, down from 752 million yuan at the beginning of the year, reflecting a decline in liquidity [10]. - The company's current ratio has been below 1 for three consecutive years, indicating a potential decline in short-term solvency [10].

--鑫融讯 2025 年 07 月 04 日 双融日报 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：79 分（较热） 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -10 0 10 20 30 (%) 沪深300 相关研究 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 79 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1。 ▌ 热点主题追踪 今日热点主题：光伏、能源金属、创新药 1、光伏主题：据上海有色网了解，为破除"内卷式"竞 争，近日国内头部光伏玻璃企业计划自 7 月开始集体减产 30％，此外部分玻璃企业堵口计划开始增多，预计后续国内 光伏玻璃供应量将快速下滑，国内供需失衡的状况将获得改 善，预计 7 月国内玻璃产量将下降至 45GW 左右。相关标的： 石英股份（603688）、爱旭股份（600732） c 2、能源金属主题：刚果金公布，2025 年 6 月 21 日起， 战略矿产市场监管局(ARECOMS)董事会采取了重大监管措施， 鉴于市场上库存量持续高企，已决定将临时禁令的期限自本 决定生 ...

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on July 3, with a total transaction volume of 1.84 billion yuan, highlighting notable trading in specific stocks such as Mindray Medical and others [1][2]. Group 1: Block Trading Overview - A total of 61 stocks underwent block trading, with a total transaction value of 1.84 billion yuan [1]. - The top three stocks by transaction value were Mindray Medical (881 million yuan), Jiuzhitang (95.6 million yuan), and Hongsoft Technology (80.1 million yuan) [1]. - Among the stocks, 11 were traded at par, 3 at a premium, and 47 at a discount [1]. Group 2: Premium and Discount Analysis - The stocks with the highest premium rates were Xiwang Food (10.4%), Tianyin Holdings (9.28%), and Huicheng Shares (2.15%) [1]. - The stocks with the highest discount rates included Betta Pharmaceuticals (22.69%), Minglida (22.46%), and Meilian New Materials (21.54%) [1]. Group 3: Institutional Trading Activity - The top institutional buy rankings were led by Mindray Medical (710 million yuan), followed by Yunnan Tourism (50.4 million yuan) and Zhongyi Technology (45.8 million yuan) [2]. - The top institutional sell rankings included Zhongke Software (42.2 million yuan), Huicheng Vacuum (29.2 million yuan), and Meilian New Materials (8.9 million yuan) [2].

Core Viewpoint - The resumption of the fifth set of standards for the Sci-Tech Innovation Board (STAR Market) is expected to revitalize the biopharmaceutical industry, which has faced a capital winter over the past two years, providing new investment opportunities and hope for long-term, capital-intensive projects [3][4][5]. Group 1: Industry Overview - The approval of Wuhan Heyuan Biotechnology Co., Ltd. (Heyuan Bio) marks the first company to pass under the restarted fifth set of standards, indicating significant market expectations and a renewed focus on the biopharmaceutical sector [3][5]. - The biopharmaceutical industry is characterized by long cycles and substantial capital requirements, making stable policy support crucial for its growth [7][8]. Group 2: Investment Insights - Investors are concerned about whether the approval standards have been raised, with expectations that companies may need to provide more robust clinical data, potentially requiring phase III clinical trials for approval [8][9]. - The commercial viability and profitability of biopharmaceutical companies will be critical under the new standards, with a focus on meeting unmet clinical needs and maintaining competitive positioning in the market [10][9]. Group 3: Company Case Study - Heyuan Bio's core product, HY1001, has completed phase III clinical trials and is projected to launch in 2025, with expectations of significant sales starting in 2026 and profitability by 2027 [9][10]. - The company has established a sales network across over 30 provinces in China through agreements with major distributors, enhancing its market presence [9]. Group 4: Market Trends - The successful listing of Heyuan Bio may lead to a resurgence of interest in Pre-IPO and mid-stage biopharmaceutical investments, which had previously stagnated due to market conditions [15][16]. - The current market environment is seeing a shift towards more rational investment behavior, with investors becoming more cautious after previous market downturns, yet maintaining a long-term optimistic outlook for the industry [17][18].

Group 1: Nanjing Business Travel - Nanjing Business Travel (600250) expects a net profit of 6 million to 9 million yuan for the first half of 2025, a decrease of 67.4% to 78.27% year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 5.5 million and 8.5 million yuan, down 17.34% to 46.52% year-on-year [1] Group 2: Jihong Co., Ltd. - Jihong Co., Ltd. (002803) anticipates a net profit of 112 million to 119 million yuan for the first half of 2025, an increase of 55% to 65% year-on-year [2] - The net profit excluding non-recurring gains and losses is expected to be between 106 million and 113 million yuan, up 68.16% to 79.62% year-on-year [2] - Basic earnings per share are projected to be between 0.29 yuan and 0.31 yuan [2] Group 3: Zhuhai Design - Zhuhai Design (300564) announced that its actual controller plans to reduce holdings by up to 3% of the company's shares, totaling 483.95 million shares [3] Group 4: Anjisi - Anjisi (688581) disclosed that two shareholders plan to reduce their holdings by up to 2% of the company's shares, totaling 162.27 million shares [4] Group 5: Jingwei Huikai - Jingwei Huikai (300120) intends to acquire a total of 12.44% equity in Nuo Si Wei, with a total transaction price of approximately 1.49 billion yuan [4] - The acquisition will increase the company's control over Nuo Si Wei from 22.12% to 34.56% [4] Group 6: Hainan Highway - Hainan Highway (000886) is planning to purchase 51% equity in Hainan Jiao Control Petrochemical, which will become a subsidiary after the transaction [9] Group 7: *ST Modern - *ST Modern (002656) has applied to revoke other risk warnings but will still face delisting risk warnings due to financial indicators [10] Group 8: Ningde Times - Ningde Times (300750) has repurchased 6.641 million A-shares at a total cost of 1.551 billion yuan [11][12] Group 9: Lixun Precision - Lixun Precision (002475) is planning to issue H shares and list on the Hong Kong Stock Exchange [13] Group 10: Ruikang Pharmaceutical - Ruikang Pharmaceutical (002589) announced that its vice president has been placed under detention by the local supervisory committee [14] Group 11: Changchun High-tech - Changchun High-tech (000661) announced that its subsidiary has received approval for a new drug, a monoclonal antibody for gout treatment [15] Group 12: Guofang Group - Guofang Group (002708) plans to reduce its holdings by up to 1.45% of the company's shares, totaling 666 million shares [16] Group 13: Guangyang Co., Ltd. - Guangyang Co., Ltd. (002708) announced that shareholders plan to reduce their holdings by up to 1.65% of the company's shares, totaling 922.76 million shares [17] Group 14: Zhixin Precision - Zhixin Precision (301512) disclosed that a major shareholder plans to reduce holdings by up to 1.86% of the company's shares, totaling 99 million shares [18] Group 15: Xinzhou Bang - Xinzhou Bang (300037) announced that its directors and executives plan to reduce their holdings by up to 126.88 million shares [19] Group 16: Guoanda - Guoanda (300902) announced that its actual controllers plan to reduce their holdings by up to 362 million shares [20]